US Pharma Giant Eli Lilly to Invest Over $1 B in India Manufactu

https://youtube.com/shorts/yw6VmUOAtUI?si=jiCH47xgpVt8XpAu

US Pharma Giant Eli Lilly to Invest Over $1 B in India Manufacturing

US pharmaceutical major Eli Lilly & Company plans to invest over US$1 billion in India to expand its contract manufacturing capabilities and reinforce supply chain resilience. The company is forging partnerships with Indian contract drugmakers and intends to set up a manufacturing and quality hub in Hyderabad to oversee production and quality assurance. The expansion is framed in response to growing global demand for its key drugs — for obesity, diabetes, Alzheimer’s, cancer, and autoimmune conditions. This move also complements Lilly’s broader investment strategy, including U.S. manufacturing growth and risk mitigation against import tariff pressures. India, already a world leader in drug production, provides a favorable ecosystem: skilled workforce, regulatory incentives, and cost advantages. By anchoring more production locally, Lilly aims to strengthen supply chain independence, accelerate distribution, and enhance global competitiveness. Observers will watch site development progress, local hiring, regulatory approvals, and how this investment influences India’s pharma trade balance. If executed well, this could signal a new wave of foreign R&D and manufacturing inflows into India’s life sciences sector.